Deep Dive: Market Access
Deep Dive/ Market Access/ Views & Analysis/ Views and analysis
Time is motor neurons – the importance of newborn screening in SMA
mike.hammerton@pharmaphorum.com
Deep Dive, Deep Dive: Market Access, market access, Mike Fraser, Novartis Gene Therapies, spinal muscular atrophy
0 Comment
Deep Dive/ Market Access/ Views & Analysis/ Views and analysis
Is it time to rethink electronic prescribing in the US?
mike.hammerton@pharmaphorum.com
Bob Katter, Deep Dive, Deep Dive: Market Access, market access
0 Comment
Deep Dive/ Market Access/ Views & Analysis/ Views and analysis
Combination pricing: access to the future of oncology treatment relies on collaboration
mike.hammerton@pharmaphorum.com
Deep Dive, Deep Dive: Market Access, market access, Oncology, Sanofi
0 Comment
Deep Dive/ Market Access/ Views & Analysis/ Views and analysis
Closing the digital expectation gap in pharma
mike.hammerton@pharmaphorum.com
Deep Dive, Deep Dive: Market Access, Jan Deman, market access, Takeda
0 Comment
Deep Dive/ Market Access/ Views & Analysis/ Views and analysis
How do we make patient centricity a reality?
mike.hammerton@pharmaphorum.com
Deep Dive, Deep Dive: Market Access, Evidation, market access, Mikki Nasch
0 Comment
Deep Dive/ Market Access/ Views & Analysis/ Views and analysis
Leveraging KOL insights to succeed in a data-driven world
mike.hammerton@pharmaphorum.com
Christina L Hoffman, Deep Dive, Deep Dive: Market Access, market access, Medscape Medical Affairs
0 Comment
Deep Dive/ Market Access/ Views & Analysis/ Views and analysis
Rethinking value: why diverse viewpoints matter
mike.hammerton@pharmaphorum.com
Axon, Deep Dive, Deep Dive: Market Access, market access, Shanida Nataraja
0 Comment
Deep Dive/ Market Access/ Views & Analysis/ Views and analysis
Building honest dialogue with patient advocates
mike.hammerton@pharmaphorum.com
Ascensia, Chris Aldred, Deep Dive, Deep Dive: Market Access, Joe Delahunty, market access
0 Comment